albertyurolaits / Depositphotos

A pair of hot pharma stocks are on the move and will turn out to be the following buzz on Wall Street. Sorrento Therapeutics (NASDAQ:SRNE), through its subsidiary Scilex Holding Company (NASDAQ:SCLX), is being profitable. That’s an enormous deal for an organization whose stock just hit penny-stock levels and is susceptible to NASDAQ delisting.

Get The Full Henry Singleton Series in PDF

Get all the 4-part series on Henry Singleton in PDF. Put it aside to your desktop, read it in your tablet, or email to your colleagues

Q4 2022 hedge fund letters, conferences and more

This Asset Manager Thinks The ESG Push Is Like The Revelations Of The Twitter Files

Environmental, social and governance (ESG) issues have drifted to the forefront of investing during the last several years, but more recently, the ESG issue has turn out to be contentious. ESG proponents claim they’re pushing corporations to be more friendly to the environment and more equitable of their governance and social issues. Nevertheless, others argue that ESG is not Read More

What this implies for investors is money flow, and that’s all the time excellent news. Assuming the momentum continues to construct, shares of Sorrento Therapeutics and Scilex could sustain a rally well into the back half of the yr.

What Is The News With Sorrento Therapeutics?

Sorrento Therapeutics is a clinical-stage biopharma company that operates in 2 segments. These are Sorrento Therapeutics and Scilex which can be a publicly listed company.

Scilex is within the business of non-opioid pain relief and has recently had a product hit the market. The news here is that sales in 2022 were a lot better than expected. The corporate released its preliminary results, which expect 2022 net revenue to are available the range of $37 to $42 million.

That’s good for a gain of 18% over last yr, and it might be higher if the accounts receivable are caught up before the accounting is finished.

Scilex got here to market only a number of months ago. The corporate IPOd via a reverse merger with SPAC Vickers Vantage Corp in November 2022, and the motion has been lower than bullish.

The revenue news has the stock on the move, but a reversal might be in play. The danger for investors in Silex is resistance on the $1.40 level, which might be fierce. Assuming the corporate’s sales can gain traction in 2023 as they did in 2022, the last word trajectory for the stock needs to be upward.

Catalysts Are In The Works For Scilex

Scilex has not 1 but 2 approved treatments. Its product Gloperba is an oral solution for the treatment of gout. Gout is a debilitating condition and one which is fueling a growth market. The present outlook is for a CAGR near 8.5% through 2030, which might be a cautious estimate. Scilex plans to launch the treatment within the US in 2023, and other candidates are within the pipeline. The three most noteworthy include 2 treatments for lower back pain/sciatica and 1 for fibromyalgia.

No analysts are covering Scilex, showing up on Marketbeat.com’s tracking tools, but not less than 2 are covering Sorrento Therapeutics. They’ve the stock pegged at a Moderate Buy with a price goal not less than 300% above the present price motion.

The range is kind of wide, however the low end is at $5, and the consensus is near $12.50, which means greater than a 1000% upside for investors. Sorrento also has a strong pipeline of products, including 5 getting ready to FDA approval. If even one makes it to the market, it would be a game-changing event for the corporate and the stock price.

The Technical Outlook: Sorrento Might Have Bottomed

Shares of Sorrento Therapeutics cratered within the wake of the IPO under short-selling pressure. Now the stock appears to be at a bottom that might turn right into a reversal, given the most recent news. Assuming the corporate and/or its subsidiary can follow through with one other win, upward price movement is assured. Until then, price motion will likely be driven by the most recent news and will be capped near the $1.80 or $3.00 level.

Must you invest $1,000 in Sorrento Therapeutics straight away?

Before you think about Sorrento Therapeutics, you’ll be wanting to listen to this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients every day. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to purchase now before the broader market catches on… and Sorrento Therapeutics wasn’t on the list.

While Sorrento Therapeutics currently has a “Buy” rating amongst analysts, top-rated analysts consider these five stocks are higher buys.

Article by Thomas Hughes, MarketBeat